Upgrade to SI Premium - Free Trial

Allogene Therapeutics (ALLO)

2.03 -0.01 (0.49%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/5/26)

Latest Headlines

Form DEFA14A Allogene Therapeutics, May 28, 2026 5:51 PM - SEC Filing Form 8-K Allogene Therapeutics, For: May 28 May 28, 2026 5:50 PM - SEC Filing Allogene Therapeutics announces CEO succession plan May 28, 2026 5:06 PM - StreetInsider Allogene Therapeutics Announces Planned CEO Succession May 28, 2026 5:02 PM - StreetInsider Allogene Therapeutics Announces Participation in Upcoming Investor Conferences May 26, 2026 8:30 AM - StreetInsider Form DEFA14A Allogene Therapeutics, May 21, 2026 6:02 AM - SEC Filing Form SCHEDULE 13G/A Allogene Therapeutics, Filed by: CITADEL ADVISORS LLC May 15, 2026 4:51 PM - SEC Filing Form SCHEDULE 13G/A Allogene Therapeutics, Filed by: Lynx1 Capital Management LP May 15, 2026 4:39 PM - SEC Filing Form SCHEDULE 13G/A Allogene Therapeutics, Filed by: Belldegrun Arie May 13, 2026 7:12 PM - SEC Filing Form SCHEDULE 13G/A Allogene Therapeutics, Filed by: Chang David D May 13, 2026 4:56 PM - SEC Filing Form 10-Q Allogene Therapeutics, For: Mar 31 May 13, 2026 4:06 PM - SEC Filing Form 8-K Allogene Therapeutics, For: May 12 May 13, 2026 4:03 PM - SEC Filing Allogene Therapeutics, Inc. (ALLO) Tops Q1 EPS by 1c May 13, 2026 4:02 PM - StreetInsider Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update May 13, 2026 4:02 PM - Globe NewsWire Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update May 6, 2026 8:30 AM - Globe NewsWire Form ARS Allogene Therapeutics, For: Dec 31 April 30, 2026 4:43 PM - SEC Filing Form DEFA14A Allogene Therapeutics, April 30, 2026 4:42 PM - SEC Filing Form DEF 14A Allogene Therapeutics, For: Jun 18 April 30, 2026 4:38 PM - SEC Filing Form 4 Allogene Therapeutics, For: Apr 21 Filed by: Yoshiyama Annie April 23, 2026 7:22 PM - SEC Filing Form SCHEDULE 13G Allogene Therapeutics, Filed by: Frazier Life Sciences Public Fund, L.P. April 23, 2026 7:13 PM - SEC Filing Form 144 Allogene Therapeutics, Filed by: Yoshiyama Annie April 21, 2026 8:22 PM - SEC Filing Allogene Therapeutics expands cancer trial to South Korea, Australia April 21, 2026 8:30 AM - StreetInsider Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia April 21, 2026 8:30 AM - StreetInsider Form PRE 14A Allogene Therapeutics, For: Apr 20 April 20, 2026 5:21 PM - SEC Filing Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026 April 20, 2026 8:30 AM - Globe NewsWire Allogene Therapeutics closes $200.4 million stock offering April 16, 2026 4:01 PM - StreetInsider Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock April 16, 2026 4:01 PM - Globe NewsWire Allogene (ALLO) PT Lowered to $11 at H.C. Wainwright April 16, 2026 7:12 AM - StreetInsider JPMorgan Upgrades Allogene (ALLO) to Neutral April 16, 2026 5:21 AM - StreetInsider Form 8-K Allogene Therapeutics, For: Apr 14 April 15, 2026 4:36 PM - SEC Filing Form 424B5 Allogene Therapeutics, April 15, 2026 4:33 PM - SEC Filing Allogene (ALLO) PT Raised to $10 at Jefferies April 15, 2026 11:56 AM - StreetInsider Allogene publishes preclinical data for dual-targeted autoimmune CAR T April 15, 2026 8:31 AM - StreetInsider Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases April 15, 2026 8:30 AM - Globe NewsWire Allogene prices $175 million stock offering at $2 per share April 14, 2026 9:50 PM - StreetInsider Allogene Therapeutics Announces Pricing of Public Offering of Common Stock April 14, 2026 9:50 PM - StreetInsider Increasing unusual call option volume: ALLO CORN CNK ALMU ADMA JBL SPIR OGN REPL ORBS LWLG CANE RVMD April 14, 2026 10:44 AM - StreetInsider Allogene (ALLO) PT Raised to $12 at H.C. Wainwright April 14, 2026 6:44 AM - StreetInsider Allogene (ALLO) PT Raised to $3.85 at Bernstein SocGen Group April 14, 2026 6:12 AM - StreetInsider Form 424B5 Allogene Therapeutics, April 13, 2026 4:45 PM - SEC Filing Allogene (ALLO) PT Raised to $8 at Citizens April 13, 2026 4:41 PM - StreetInsider Form 8-K Allogene Therapeutics, For: Apr 13 April 13, 2026 4:09 PM - SEC Filing Allogene announces $175 million public stock offering April 13, 2026 4:01 PM - StreetInsider Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock April 13, 2026 4:01 PM - StreetInsider Oppenheimer on Allogene (ALLO): 'data represents strong early validation of the ALPHA3 strategy' April 13, 2026 12:04 PM - StreetInsider Jefferies on Allogene (ALLO): expecting strong stock momentum into Cema-cel interim/prelim EFS readouts April 13, 2026 11:13 AM - StreetInsider Allogene (ALLO) PT Raised to $9 at Baird April 13, 2026 8:50 AM - StreetInsider Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics’ MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma April 13, 2026 8:00 AM - BizWire Form 8-K Allogene Therapeutics, For: Apr 13 April 13, 2026 7:45 AM - SEC Filing Allogene reports 58% disease clearance rate in lymphoma trial April 13, 2026 7:31 AM - StreetInsider Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Con April 13, 2026 7:30 AM - Globe NewsWire Allogene Therapeutics (ALLO) Halted, News Pending April 13, 2026 7:27 AM - StreetInsider Allogene Therapeutics schedules conference call for ALPHA3 trial data April 10, 2026 4:02 PM - StreetInsider Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, April 10, 2026 4:02 PM - StreetInsider Jefferies Assumes Allogene (ALLO) at Buy April 10, 2026 1:56 AM - StreetInsider Form 4 Allogene Therapeutics, For: Mar 31 Filed by: Beneski Benjamin Machinas April 2, 2026 4:48 PM - SEC Filing Form 144 Allogene Therapeutics, Filed by: Beneski Benjamin Machinas April 1, 2026 7:14 PM - SEC Filing Form 4 Allogene Therapeutics, For: Mar 16 Filed by: Beneski Benjamin Machinas March 18, 2026 4:08 PM - SEC Filing Form 4 Allogene Therapeutics, For: Mar 16 Filed by: Chang David D March 18, 2026 4:07 PM - SEC Filing Form 144 Allogene Therapeutics, Filed by: Beneski Benjamin Machinas March 16, 2026 8:20 PM - SEC Filing Form 144 Allogene Therapeutics, Filed by: Chang David D March 16, 2026 8:05 PM - SEC Filing Citizens on Allogene (ALLO): 'We View Shares as an Attractive Investment Opportunity' March 16, 2026 4:47 AM - StreetInsider Allogene (ALLO) PT Raised to $8 at Piper Sandler March 13, 2026 9:02 AM - StreetInsider Form S-8 Allogene Therapeutics, March 12, 2026 4:37 PM - SEC Filing Allogene Therapeutics, Inc. (ALLO) Tops Q4 EPS by 6c March 12, 2026 4:27 PM - StreetInsider Form 10-K Allogene Therapeutics, For: Dec 31 March 12, 2026 4:13 PM - SEC Filing Form 8-K Allogene Therapeutics, For: Mar 12 March 12, 2026 4:09 PM - SEC Filing Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update  March 12, 2026 4:02 PM - StreetInsider Full Article List